Financial Performance Expectations - The company expects a net loss for the fiscal year 2025, estimated between 76.24 million and 99.12 million CNY, compared to a loss of 62.67 million CNY in the same period last year, representing a decline of 21.67% to 58.17%[3] - The net loss after deducting non-recurring gains and losses is projected to be between 82.25 million and 106.92 million CNY, compared to a loss of 66.45 million CNY in the previous year, indicating a decrease of 23.77% to 60.90%[3] Sales and Market Impact - The significant decline in performance is primarily due to a sharp decrease in sales volume and price of sodium acetate Ringer's injection, which was awarded in the 10th batch of national centralized drug procurement at the end of 2024, effective from April 2025[5][6] Subsidiary Contributions - The subsidiary Sichuan Duori completed its acquisition in November 2024 and is expected to contribute to revenue growth in 2025, although it has not yet covered R&D and financial expenses, resulting in continued losses[6]
多瑞医药(301075) - 2025 Q4 - 年度业绩预告